PReparing for Optimal Phase III/IV maTErnal Group B StreptococCal vaccine Trials in Africa (PROTECT)

Ciutat:
Poster European Corner

 

 

PReparing for Optimal Phase III/IV maTErnal Group B StreptococCal vaccine Trials in Africa (PROTECT)

Número del projecte / Project number

101145724

Nom i cognoms / Name and surname

Azucena Bardají, Kirsty Le Doare, Eve Nakabembe, Sergio Massora, Kondwani Kawaza, Robert Mboizi, Angela Koech

Afiliació / Affiliation

Instituto de Salud Global de Barcelona

Breu explicació del projecte / Brief explanation of your project

Two vaccines designed for pregnant women to protect their unborn infant are entering late-phase development and will prevent infections from group B Streptococcus and respiratory syncytial virus, respectively. For these vaccines to be approved, they must work effectively without causing any unwanted responses. To implement these vaccines in countries with low resources, healthcare systems must be strengthened by improving vaccine safety monitoring and surveillance of infection and advancing vaccine delivery, vaccine confidence, and patient participation. The rapid rollout of electronic health records (EHR) in Kenya, Mozambique, Malawi, and Uganda offers an opportunity to use routine data to strengthen reporting of rates of adverse pregnancy, neonatal and infant outcomes, and any adverse events following immunisation; this will be imperative in informing and preparing for future large scale vaccination rollout campaigns.

Our approach will address key gaps in EHR to develop pregnancy registries embedded within national reporting systems to establish this data, including baseline rates of pregnancy and infancy outcomes for Tetanus and COVID-19 vaccines currently in use. These reporting systems will allow monitoring of potential safety signals once new vaccines are introduced. Experts in EHR, obstetrics and gynaecology, paediatrics, microbiology, clinical trials, and implementation research will develop the motivation and tools needed to monitor and evaluate current and future maternal vaccines.

We will work closely with the WHO, African Medicines Agency and country stakeholders, co-developing pregnancy registries, sentinel site microbiological surveillance systems, and maternal vaccination communications toolkits in preparation for the decade of maternal vaccines. Our programme of work culminates in a network of maternal vaccine trial sites that can rapidly evaluate vaccines in pregnancy from late-stage trials through to introduction on a national level.

Enllaç a la pàgina web del projecte / Link to your project website

https://www.protect-network.org/

Repte en que s’emmarca aquest projecte / Challenge within the framework of this project

Coordinen:

Amb el suport de:

Amb el finançament de:

Aquest projecte està cofinançat pel programa de recerca i innovació Horizon Europe de la Unió Europea sota el projecte NitRecerCat2425 (101162003).

This project is co-funded by the European Union’s research and innovation programme Horizon Europe, under the project NitRecercat2425 (101162003).